Surrogate Virus Neutralization Test (sVNT) to determine salivary neutralizing antibody inhibition of ACE2 and SARS-CoV-2 Spike RBD complex
-
By
-
Forsman, David
-
Smith, Abigail Rose
-
Pratt, Alex
-
Comerford, Paige
-
Sparano, Fiona
-
Peng, Congyue
-
Dean, Delphine
-
May 21, 2026
-
Clinical Scorecard: Assessment of Salivary Neutralizing Antibody Activity Against ACE2 and SARS-CoV-2 Spike RBD Complex Using Surrogate Virus Neutralization Testing (sVNT)
At a Glance
| Category | Detail |
|---|
| Condition | SARS-CoV-2 infection |
| Key Mechanisms | Neutralizing antibodies block the binding of the spike protein to hACE-2. |
| Target Population | Individuals vaccinated with the Pfizer vaccine. |
| Care Setting | Laboratory testing for neutralizing antibody activity. |
Key Highlights
- Laboratory-developed sVNT assesses neutralizing activity of saliva antibodies.
- Saliva antibodies can neutralize the reference SARS-CoV-2 spike RBD.
- Omicron variant spike RBD shows escape from mucosal immune defense.
- Analytical sensitivity and specificity of sVNT comparable to FDA-approved tests.
- Experience gained can be applied to other pathogens.
Guideline-Based Recommendations
Diagnosis
- Use sVNT to assess neutralizing antibody activity in saliva.
Management
- Monitor neutralizing activity against variants, particularly Omicron.
Monitoring & Follow-up
- Evaluate immune protection through surrogate neutralization tests.
Risks
- Omicron variant may evade mucosal immune defenses.
Patient & Prescribing Data
Donors who completed two doses of the Pfizer vaccine and received a booster.
Saliva antibodies may provide insights into mucosal immunity.
Clinical Best Practices
- Consider saliva testing for neutralizing antibodies in vaccinated individuals.
- Stay updated on variant-specific neutralization capabilities.
Related Resources & Content
